Current Management for MRONJ: An Evidence-Based Approach
-
You must log in to register
- Member - $60
- Resident Member - Free!
- Allied Staff Member - $60
- Professional Staff Nonmember - $120
- Other Nonmember - $120
- Practice Management CE Subscriber - $60
- CE Subscriber (Clinical & PM) - Free!
Medication-related osteonecrosis of the jaw (MRONJ) is a condition that has created numerous dilemmas in patient management and may have a broad health impact for patients with cancer and osteoporosis. While MRONJ was initially associated with antiresorptive medications, today there is substantial data to suggest other types of drugs and comorbidities implicated in the pathogenesis. This case-based session will review evidence-based data and innovative strategies for diagnosis, risk assessment, prevention and management of MRONJ with related outcomes and complications.
Learning Objectives
At the conclusion of this program, participants should be able to:
- Describe how to navigate the oral health and medical dilemmas associated with patients who undergo antiresorptive therapy.
- Understand management options for patients with various stages of MRONJ and how to provide the best outcomes for improving oral health and quality of life.
- Recognize anatomic changes, risk factors and potential complications that impact outcome when treating MRONJ.
- Discuss current evidence related to the pathogenesis of osteonecrosis of the jaw.
Kenneth E. Fleisher, DDS, FACS
Clinical Professor
Bellevue Hospital Center/NYU Langone Health
New York, New York
Disclosure(s): No financial relationships to disclose
An Internet-based CDE/CME Activity
Original Release Date: September 20, 2025
Expiration Date: September 20, 2028
Estimated time to complete this educational activity: 1 hour
Method of participation: Self-Study
Kenneth E. Fleisher, DDS
Clinical Professor
Bellevue Hospital Center/ NYU Langone Health
Dr. Fleisher is a Clinical Professor in the Department of Oral and Maxillofacial Surgery at the New York University College of Dentistry and an attending surgeon at the Bellevue Hospital Center and New York University Langone Medical Center in the department of Plastic Surgery. He participates in the didactic and clinical training of dental students, international dentists and postgraduate oral and maxillofacial surgery residents. Dr. Fleisher’s is committed to scholarship and teaching, and he is the recipient of the AAOMS Faculty Educator Development Award. Dr. Fleisher is recognized by NYU Dentistry, NYU Langone Medical Center, and Bellevue Hospital for his clinical expertise in managing patients with necrotic bone diseases such as medication-related osteonecrosis of the jaw (MRONJ) and osteoradionecrosis.
Disclosures: No financial relationships to disclose
Continuing Education Provider Approval
The American Association of Oral and Maxillofacial Surgeons is an ADA CERP Recognized Provider.
ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education.
ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry.
The American Association of Oral and Maxillofacial Surgeons designates this activity for 1.25 continuing education credit(s).
AGD - Accepted Program Provider
FAGD/MAGD Credit
11/1/22-12/31/26
Provider ID# 214680
The American Association of Oral and Maxillofacial Surgeons (AAOMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Association of Oral and Maxillofacial Surgeons designates this internet-based enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Key:
Complete
Next
Failed
Available
Locked